Histogenics

Histogenics is a biotechnology company that focuses on the development of restorative cell therapies. Histogenics develops restorative cell therapies that may offer rapid-onset pain relief and restored function, and its technology platform has the potential to be used for a broad range of restorative cell therapy indications.

Histogenics has merged with Ocugen, a clinical stage biopharmaceutical company that focuses on discovering, developing and commercializing a pipeline of innovative therapies that address rare eye diseases, and the merger has resulted in a combined clinical-stage biopharmaceutical company that is operating under the "Ocugen" name.

Since the company has become Ocugen, it has sought to develop innovative therapies to treat rare and underserved eye diseases through a combination of therapeutic approaches that utilize small molecules, biologics, and gene therapies. The company has developed a wide pipeline which includes OCU300, an orphan drug candidate for ocular graft versus host disease, and OCU310 for dry eye disease; its modifier gene therapy platform and OCU400, a gene augmentation therapy for patients with inherited retinal diseases caused by mutations in the NR2E3 gene, which recently received orphan drug designation from the FDA.

The company has also made pre-clinical progress toward its retinal disease programs which includes novel biologic therapies for wet-age-related macular degeneration, diabetic macular edema and diabetic retinopathy, as well as for retinitis pigmentosa.”

Ocugen’s broad pipeline of promising ophthalmology programs in development include: Modifier Gene Therapy Platform, Ocular Surface Disease Programs, and Retinal Disease Programs,